• Standard BioTools filed an amended Form 8-K to correct its July 28, 2026 report by adding the Share and Asset Purchase Agreement.
• The agreement covers the planned sale of its mass cytometry business to Multiplex Bio.
• No other changes were made to the original 8-K.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-029964), on July 29, 2026, and is solely responsible for the information contained therein.